Skip to main content

Advertisement

Table 1 The baseline clinicopathologic characteristics of underweight, normal weight, overweight, and obese patients with stage I NSCLC, stratified by BMI

From: Effect of body mass index on survival of patients with stage I non-small cell lung cancer

Characteristic Overall (cases) Underweight [cases (%)] Normal weight [cases (%)] Overweight [cases (%)] Obese [cases (%)] P value
Total 624 44 245 306 29  
Gender       0.668
 Male 408 (65.4) 26 (13.6) 166 (67.8) 198 (64.7) 18 (62.1)  
 Female 216 (34.6) 18 (86.4) 79 (32.2) 108 (35.3) 11 (37.9)  
Age (years)       0.991
 <60 285 (45.7) 20 (2.3) 114 (46.5) 138 (45.1) 13 (44.8)  
 ≥60 339 (54.3) 24 (97.7) 131 (53.5) 168 (54.9) 16 (55.2)  
Smoking       0.001
 Never 318 (51.0) 23 (4.5) 101 (41.2) 178 (58.2) 16 (55.2)  
 Current or ever 306 (49.0) 21 (95.5) 144 (58.8) 128 (41.8) 13 (44.8)  
Hypertension       <0.001
 With 150 (24.0) 6 (13.6) 38 (15.5) 93 (30.4) 13 (44.8)  
 Without 474 (76.0) 38 (86.4) 207 (84.5) 213 (69.6) 16 (55.2)  
Diabetes       0.318
 With 46 (7.4) 1 (2.3) 18 (7.3) 23 (7.5) 4 (13.8)  
 Without 578 (92.6) 43 (97.7) 227 (92.7) 283 (92.5) 25 (86.2)  
Heart disease       0.482
 With 18 (2.9) 2 (4.5) 7 (2.9) 7 (2.3) 2 (6.9)  
 Without 606 (97.1) 42 (95.5) 238 (97.1) 299 (97.7) 27 (93.1)  
FEV1/FVC (%)       0.011
 <70 83 (13.3) 11 (25.0) 40 (16.3) 30 (9.8) 2 (6.9)  
 ≥70 541 (86.7) 33 (75.0) 205 (83.7) 276 (90.2) 27 (93.1)  
Type of surgery       0.979
 Open thoracotomy 537 (86.1) 37 (84.1) 210 (85.7) 264 (86.3) 25 (86.2)  
 VATS 87 (13.9) 7 (15.9) 35 (14.3) 42(13.7) 4 (13.8)  
Extent of resection       0.681
 Lobectomy or bilobectomy 611 (97.9) 44 (100.0) 239 (97.6) 299 (97.7) 29 (100.0)  
 Pneumonectomy 13 (2.1) 0 (0.0) 6 (2.4) 7 (2.3) 0 (0.0)  
Adjuvant chemotherapy       0.967
 Absent 486 (77.9) 34 (77.3) 193 (78.8) 236 (77.1) 23 (79.3)  
 Present 138 (22.1) 10 (22.7) 52 (21.2) 70 (22.9) 6 (20.7)  
Histological type       0.432
 Adenocarcinoma 406 (65.1) 29 (65.9) 152 (62.0) 203 (66.3) 22 (75.9)  
 Squamous cell carcinoma 140 (22.4) 12 (27.3) 62 (25.3) 63 (20.6) 3 (10.3)  
 Other NSCLC 78 (12.5) 3 (6.8) 31 (12.7) 40 (13.1) 4 (13.8)  
Histologic differentiation       0.131
 Poor 212 (34.0) 17 (38.6) 94 (38.4) 92 (30.1) 9 (31.0)  
 Moderate 300 (48.1) 17 (38.6) 113 (46.1) 159 (52.0) 11 (37.9)  
 Well 112 (17.9) 10 (22.7) 38 (15.5) 55 (18.0) 9 (31.0)  
Visceral pleural invasion       0.005
 Absent 408 (65.4) 32 (72.7) 140 (57.1) 212 (69.3) 23 (79.3)  
 Present 216 (34.6) 12 (27.3) 105 (42.9) 94 (30.7) 6 (20.7)  
T stage       <0.001
 T1a 132 (21.2) 10 (22.7) 36 (14.7) 78 (25.5) 8 (27.6)  
 T1b 113 (18.1) 13 (29.5) 31 (12.7) 59 (19.3) 9 (31.0)  
 T2a 379 (60.7) 21 (47.7) 178 (72.7) 169 (55.2) 12 (41.4)  
Clinical TNM stage       <0.001
 IA 245 (39.3) 23 (52.3) 67 (27.3) 137 (44.8) 17 (58.6)  
 IB 379 (60.7) 21 (47.7) 178 (72.7) 169 (55.2) 12 (41.4)  
  1. Underweight BMI < 18.5 kg/m2; normal weight BMI 18.5–22.4 kg/m2; overweight BMI = 22.5–28.0 kg/m2; obese BMI > 28.0 kg/m2
  2. NSCLC non-small cell lung cancer, BMI body mass index, FEV1/FVC forced expiratory volume in 1 s/forced vital capacity, VATS video-assisted thoracic surgery